Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-24 @ 3:52 PM
Ignite Modification Date:
2025-12-24 @ 3:52 PM
NCT ID:
NCT02253992
Brief Summary:
The purpose of this study is to determine which doses of Urelumab and Nivolumab are safe and tolerable when they are given together.
Study:
NCT02253992
Study Brief:
Protocol Section:
NCT02253992